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Aim of the study: To evaluate out-
come, costs and treatment differenc-
es in rectal cancer patients between 
various regions in Poland.
Material and methods: Data from 
the Polish National Health Fund of all 
patients with rectal cancer diagnosed 
and treated between 2005 and 2007 
were analyzed. Overall, relative 5-year 
survival and the percentage of pa-
tients receiving chemotherapy, radio-
therapy and surgery were analyzed. 
The possible influence of cost of treat-
ment per patient and mean number 
of rectal cancer patients per surgical 
oncologist were analyzed as well.
Results: In total 15,281 patients with 
rectal cancer were diagnosed and 
treated in Poland in 2005–2007 with-
in the services of the National Health 
Fund. The overall, relative 5-year sur-
vival rate was 51.6%. Curative surgery 
was performed in 64.1% of patients. 
Radiotherapy and chemotherapy were 
used in 47.5% and 60.7% of patients, 
respectively. The mean cost of treat-
ment of one rectal cancer patient was 
32,800 PLN and there were 49.8 rectal 
cancer patients per specialist in sur-
gical oncology. Important differences 
between regions were found in all 
these factors, but without a  signifi-
cant influence on survival. A  correla-
tion between numbers of patients per 
specialist in different voivodeships 
and survival rates was observed, as 
well as a correlation between percent-
age of surgical resection in voivode-
ships and survival rates (p = 0.07).
Conclusions: Results of treatment of 
colorectal cancer in Poland improved 
significantly during the last decade. 
There exist however, important dis-
parities between regions in terms of 
method of treatment, costs and out-
comes.
Key words: rectal cancer, prognosis, 
registries, treatment outcome.
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Introduction
Many studies have shown important variations in the treatment modal-
ities and outcome between hospitals [1, 2]. The regional and between-hos-
pital differences can only partially be explained by the different volume and 
case mix that every hospital manages [3].
In Poland, colorectal cancer incidence and mortality are on a steady rise in 
almost all regions [4]. The implementation of national guidelines, which has 
been shown in other countries to improve outcomes in rectal cancer [5], has 
been introduced in Poland. Unfortunately, even with the implementation of 
the Polish national guidelines for the treatment of colorectal cancers, there 
are important regional differences in terms of adherence to the guidelines 
and outcomes of treatment.
In the literature there are conflicting data on whether the differences in 
treatment modalities of patients with rectal cancer influence outcome. An 
association between hospital volume and outcome has been reported by 
some and denied by others [6–10]. Also the analysis of the type of hospital 
(university hospital, community or county hospital) has shown conflicting 
results [11, 12].
In this study we analyzed regional differences and outcomes in the treat-
ment modalities used to treat rectal cancer patients. We also tried to iden-
tify which factors are responsible for the differences in overall survival be-
tween regions.
Material and methods
In Poland, all newly diagnosed cancers should be registered in the na-
tionwide National Cancer Registry. The data are provided by all hospitals at 
the moment when a new cancer case is diagnosed, and at the same time 
the cancer should be staged according to the newest version of the TNM 
classification [13]. On the other hand, the National Health Fund (Narodowy 
Fundusz Zdrowia, NFZ) is obliged to ensure and cover the costs of treatment 
of all patients within the system. There is only a small number of oncological 
patients treated out of this system. To allow for analysis of the costs borne 
by the system and the results of treatment, a series of coding systems are 
used for every patient. For coding of the tumor site and type the Internation-
al Classification of Diseases is used [14]. Unfortunately, there are no data on 
cancer stage in the system yet. The calculation of the costs is based on the 
same data. The law in Poland does not require the national insurer (NFZ) to 
cover the actual costs of a procedure.
The outcomes of patients with colorectal cancer treated in 2005–2007 
were compared to those treated in 2000–2002. We compared results for the 
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colon and rectal cancer group as a whole because there 
was no information about 5-year survival rates of the sub-
group of rectal cancer patients treated previously. Survival 
data from the years 2000–2002 were obtained from the 
National Cancer Registry, as there were no similar data 
available from the National Health Fund.
Statistical methods
For statistical analysis we used Statistica 10 for Win-
dows. Univariate and multivariate analysis of the available 
data was performed.
Patients
In Poland 41,287 patients were diagnosed with colorec-
tal cancer from 2005 to 2007. Data of all patients with in-
vasive rectal cancer diagnosed and treated between 2005 
and 2007 within the National Health Fund system in Po-
land were selected for the study (n = 15,281).
Regions, hospitals, surgeons
Poland is divided into 17 regions (voivodeships). There 
exist important differences between regions in terms of 
population, income per capita and centralization of cancer 
care (not all regions have a dedicated cancer center). Also, 
in regions with a dedicated cancer center not all cancer pa-
tients are treated there, as many patients are treated in uni-
versity and community or county hospitals. In Poland there 
is a subspecialty called surgical oncology, and the majority 
of surgical oncologists are general surgeons with two ad-
ditional years of training in cancer centers. However, there 
is no legal obligation that would require all cancer patients 
to be treated by surgeons with this particular subspecialty. 
Some of the operations for rectal cancer are performed by 
general surgeons and some by surgical oncologists (who 




Relative 5-year survival was 52.8% for the whole col-
orectal patient group treated between 2005 and 2007 
(ranging in voivodeships from 48.1% to 56.1%). Compari-
son (Fig. 1) of current and historical data for all regions in 
Poland shows an important rise in the outcomes. Five-year 
survival in the years 2000–2002 was 43.7% and ranged 
depending on the region from 36.3% to 45.7%. When com-
paring data for each region separately for both periods we 
found that rates rose for every region from 8% to 12.5% 
(mean rise of 9.1%).
Rectal cancer
There was an 8.4% difference in relative 5-year survival 
rate between Polish voivodeships (47.1% to 55.5%; mean 
51.6%) (Fig. 2).
Radiotherapy was used in 47.5% of patients (33.5% to 
59.4% depending on the region, Fig. 3). The use of radiother-
apy in each region did not influence overall 5-year survival 
rates (p = 0.26) (Fig. 4).
Chemotherapy (adjuvant or neoadjuvant) was used in 
60.7% (51.4% to 75.3% depending on the region) of patients 
(Fig. 5). The use of chemotherapy in each region did not in-
fluence overall 5-year survival rates (p = 0.28) (Fig. 6).
Surgery with curative intent was performed in 64.1% 
(45.5% to 70.6% depending on the region) of patients (Fig. 
7). We observed a trend toward better survival rates in re-
gions with more radical surgery cases, although this trend 
did not reach the level of statistical significance (p = 0.07) 
(Fig. 8).
Analysis of percentages of hepatic metastasectomies 
performed in rectal cancer patients showed significant dif-
ferences between voivodeships; mean 1.5% (range 0.25–
2.5%) (Fig. 9).










































































































years 2005–2007; mean 52.8% (48.1–56.1%)
years 2000–2002; mean 43.7% (36.3–45.7%)
Relative 5-year survival rates for colorectal cancer patients. 
















We also looked at the mean number of rectal cancer 
patients per surgical oncologist in each region. These 
numbers showed important variations among regions and 
ranged from 28 to 114 patients/specialist (mean 50) (Fig. 
10). We did not find a statistically significant relation but 
only a trend between the number of patients per surgical 
oncologist per region and the 5-year overall survival rate 
(p = 0.07) (Fig. 11). It is important to note, however, that 
this number does not represent the actual workload of 
each surgical oncologist but only the number of patients 
in a particular region divided by the number of surgical 
oncologists practicing in this region, without taking into 
account the number of general surgeons and coloproctolo-
gists who take care of these patients.











































































































Relative 5-year survival rates for rectal cancer patients treated in 2005–2007






























































































































Rate of rectal cancer patients received irradiation therapy 
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Costs
The mean cost of treatment of rectal cancer patient was 
32,800 Polish zloty (PLN) (7,800 EUR; EUR = 4.2 PLN) (Fig. 
12). Mean cost of surgery was 6500 PLN (1540 EUR), mean 
cost of radiotherapy was 7200 PLN (1700 EUR) and of che-
motherapy was 18,300 (4340 EUR). The differences between 
regions in the mean costs of treatment were important and 
ranged from 29,300 PLN (6,900 EUR) to 38,500 PLN (9,140 
EUR). The different costs of treatment in each voivodeship 
were analyzed to find whether there is a relation between 
cost of treatment and overall survival in a region. When 
data for all regions were compared, we found no statisti-
cally significant differences in terms of 5-year survival rates 
for each region (Fig. 13). Interestingly we also failed to find 











































































































Relative 5-year survival rates of rectal patients and rate of patients received irradiation therapy

















































































































































Rate of rectal cancer patients received chemotherapy





































































































































Percentage of rectal cancer patients treated with surgical resection







































































































































Relative 5-year survival rates of rectal patients and rate of patients received chemotherapy






































a statistically significant correlation between the cost of 
treatment in each region and the incidence of chemothera-
py (adjuvant or neoadjuvant), radiotherapy or surgery.
Discussion
In this nationwide population-based study evaluating 
National Health Fund data of 15,281 patients with rectal 
cancer diagnosed and treated in Poland in the period from 
2005 to 2007, we found important differences in treat-
ment modalities and outcomes between regions.
The relative 5-year survival rate of 52% observed in this 
analysis is disturbingly lower when compared to the figures 
from the USA (66%) [15], the United Kingdom (56%) [16] or 
Norway (66%) [17]. On the other hand, only a few years ago 
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the figures for 5-year survival were much lower for all re-
gions and rose by an average of 9.1% during this time span. 
This important step forward can be partially explained by 
the introduction of the guidelines in the treatment of rectal 
cancer, which has been shown to improve outcomes [5].
The current standard of care in Poland requires that for 
the treatment of rectal cancer patients with stage III and 











































































































Relative 5-year survival rates of rectal patients and rate of patients after surgical resection



























































































































































Percentage of rectal cancer patients after hepatic metastasectomy
















locally advanced stage II tumors without distant metasta-
sis receive radio-chemotherapy or radiotherapy preceding 
resection to reduce the risk of local recurrence [18]. In our 
study we found important variations between regions in 
terms of incidence of radiotherapy ranging from 33.5% to 
59.4%. While the higher numbers are similar to numbers in 




Fig. 10. Number of rectal cancer patients per specialist (oncological surgeon)





















































































































































































































Number of rectal cancer patients per specialist (oncological surgeon)
(in voivodeships mean 49.8 [27.5–114)
Relative 5-year survival rates of rectal patients and number of patients per specialist (oncological surgeon)





























































the numbers for some Polish regions are definitely too low, 
even taking into account a different case mix. The differenc-
es in the approach to preoperative radiotherapy between 
surgeons and hospitals despite clear and unified national 
criteria are a constant finding in other publications. A Kore-
an questionnaire study showed that surgeons in university 
hospitals are more likely to refer patients with rectal cancer 
for preoperative radiotherapy [19]. However, Dutch results 
showed that patients diagnosed in a teaching hospital were 
less likely to receive preoperative radiotherapy [3].
Interestingly, we could not find a statistically significant 
correlation between the incidence of radiotherapy in a re-
gion and probability of overall survival. This finding can be 
explained by reports confirming that preoperative radio-
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chemotherapy can indeed lower local recurrence rate but 
at the same time may have no influence on overall survival 
[20]. However, it should be underlined that in our study 
we did not analyze the influence of regional differences 
in case mix on the outcome. Thus, it is possible that the 
differences in incidence of radiotherapy mirror important 
differences in the tumor burden in each regional patient 
population.
Similar disparities were observed between regions in 
terms of chemotherapy treatment. Once again, we ob-
served no statistically significant correlation between che-
motherapy treatment and overall survival probability in 
Fig. 12. Costs of treatment of patients with rectal cancer






















































































































































































































Costs treatment patients with rectal cancer (in tousands PLN per patients)
(in voivodeships mean 32.8/pt [29.3–38.5])
Relative 5-year survival rates of rectal patients and costs of patients treatment


















































each region. Adjuvant and neoadjuvant chemotherapy has 
been shown to influence both disease-free [21] and over-
all survival [22]. Therefore, our results probably reflect the 
differences in the stage of the disease between regions.
The high variation in the incidence of surgery with cura-
tive intent (45.5% to 70.6% depending on the region) is prob-
ably a reflection of different stage of disease as well. But this 
is only a partial explanation. One should bear in mind that 
even currently in Poland about 50–60% of cases of colorectal 
cancer are diagnosed and treated at stage III and IV [4]. The 
influence of performing surgery with curative intent on over-
all survival was the strongest single factor influencing sur-
vival in our study, but it did not reach statistical significance.
Another factor that showed a trend toward reaching 
statistical significance was the impact of the mean number 
of rectal cancer patients per surgical oncologist in each re-
gion on survival. This finding is difficult to interpret due to 
the specific nature of this subspecialty in Poland and the 
fact that many general surgeons without formal surgical 
oncology training perform rectal cancer surgery as well. It 
seems likely that these two findings (surgical resection per-
centages and number of patients per specialist with their 
influences on survival) may indicate differences in quality 
of treatment of rectal cancer patients.
Another finding that came as a surprise was the low in-
cidence of hepatic resection in the study group. The 1.5% 
of rectal cancer patients undergoing liver resection for me-
tastasis is much lower than the 6.1% reported in the North 
American study on Medicare beneficiaries [23]. This number 
seems very low. It is not clear why so few rectal cancer pa-
tients underwent hepatic resection. One explanation could 
be the low number of dedicated hepatopancreaticobiliary 
(HPB) centers in Poland (currently only 6 centers in Poland 
have an advanced HPB and liver transplant program).
The cost of treatment of rectal cancer patients in Poland 
was significantly lower than the same costs in Poland’s 
western neighbor, Germany. The mean of 7,800 EURO paid 
in Poland is far from the 15,000 EURO to 21,300 EURO for 
early stages and from 29,800 EURO to 35,000 EURO for 
late stages reported by the German insurance system [24]. 
Similar numbers have been reported in France, where the 
mean cost of a year of treatment of a colorectal cancer 
patient has been found to be 24,966 EURO. The French 
analysis also showed the influence of stage on the total 
cost of care, with cost of treatment of stage I colorectal 
cancer of 17,596 EURO and 35,059 EURO for stage IV [25]. 
In our study no correlation was found between the cost 
of treatment of a rectal cancer patient in each region and 
the overall survival. Interestingly, we also failed to identi-
fy a correlation between higher cost and the probability 
of chemotherapy, radiotherapy or curative surgery treat-
ment. While we cannot fully explain these findings, it is 
somewhat reassuring that lower costs of treatment in 
some regions in our study were not correlated with poorer 
survival.
In conclusion, despite the existence of the national 
treatment guidelines in Poland, there are important dis-
parities between regions in terms of type of treatment, 
overall survival and costs. In the last few years we have 
observed a major improvement in the results of treatment 
of rectal cancer, but they are still worse than the results in 
the USA and Western Europe. 
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